Perfusion/Diffusion Mismatch Is Valid and Should Be Used for Selecting Delayed Interventions

Translational Stroke Research

Volumn 3, Issue 2, 2012, Pages 188-197

  Davis, Stephen ^a   Campbell, Bruce ^a   Christensen, Soren ^a   Ma, Henry ^a   Desmond, Patricia ^a   Parsons, Mark ^c   Levi, Christopher ^c   Bladin, Christopher ^b   Barber, P Alan ^d   Donnan, Geoffrey ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Ischemic penumbra; Mismatch; MRI; Stroke; Therapy

Indexed keywords

ALTEPLASE; DESMOTEPLASE; PLACEBO; PROUROKINASE; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

BRAIN BLOOD FLOW; BRAIN BLOOD VOLUME; BRAIN ISCHEMIA; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTED TOMOGRAPHY PERFUSION; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; ECHO PLANAR IMAGING; EMBOLECTOMY; FIBRINOLYTIC THERAPY; HUMAN; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN EXTRACTION FRACTION; PATIENT SELECTION; PERFUSION DIFFUSION MISMATCH; PERFUSION WEIGHTED IMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECANALIZATION; REVIEW; SCINTIGRAPHY; STROKE; THERAPY DELAY; THROMBOEMBOLISM;

EID: 84861700829     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-012-0167-8     Document Type: Review

References (55)

1. NINDS. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995; 333(24): 1581-7.
2. Lees KR, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010; 375(9727): 1695-703.
3. Sandercock P, et al. The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke. Trials. 2008; 9(1): 37.
4. Donnan GA, et al. Penumbral selection of patients for trials of acute stroke therapy. Lancet Neurol. 2009; 8(3): 261-9.
5. Astrup J, Siesjo BK, Symon L. Thresholds in cerebral ischemia-the ischemic penumbra. Stroke. 1981; 12(6): 723-5.
6. Darby DG, et al. Pathophysiological topography of acute ischemia by combined diffusion-weighted and perfusion MRI. Stroke. 1999; 30(10): 2043-52.
7. Hacke W, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005; 36(1): 66-73.
8. Furlan AJ, et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. 2006; 37(5): 1227-31.
9. Parsons MW, et al. Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window. Neurology. 2009; 72(10): 915-21.
10. Hacke W, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2009; 8(2): 141-50.
11. Smith WS, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke. 2005; 36(7): 1432-8.
12. Smith WS, et al. Mechanical thrombectomy for acute ischemic stroke: final results of the multi MERCI trial. Stroke. 2008; 39(4): 1205-12.
13. Furlan A, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism. JAMA. 1999; 282(21): 2003-11.
14. Parsons MW, et al. A randomized trial of tenecteplase and alteplase for acute ischemic stroke. N Engl J Med. 2012; 366(12): 1099-107.
15. Baker WL, et al. Neurothrombectomy devices for the treatment of acute ischemic stroke: state of the evidence. Ann Intern Med. 2011; 154(4): 243-52.
16. Sit SP. The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke. 2009; 40(8): 2761-8.
17. Costalat V, et al. Rescue, Combined, and stand-alone thrombectomy in the management of large vessel occlusion stroke using the solitaire device: a prospective 50-patient single-center study: timing, safety, and efficacy. Stroke. 2011; 42(7): 1929-35.
18. Saver J, et al. Primary Results of the SOLITAIRE FR With the Intention for Thrombectomy (SWIFT) Multicenter, Randomized Clinical Trial. International Stroke Conference Late-breaking abstract. 2012.
19. Khatri P, et al. Methodology of the Interventional Management of Stroke III Trial. Int J Stroke. 2008; 3(2): 130-7.
20. Ackerman RH, et al. Positron imaging in ischemic stroke disease using compounds labeled with oxygen 15. Initial results of clinicophysiologic correlations. Arch Neurol. 1981; 38(9): 537-43.
21. Baron JC, et al. Local interrelationships of cerebral oxygen consumption and glucose utilization in normal subjects and in ischemic stroke patients: a positron tomography study. J Cereb Blood Flow Metab. 1984; 4(2): 140-9.
22. Wise RJ, et al. Serial observations on the pathophysiology of acute stroke. The transition from ischaemia to infarction as reflected in regional oxygen extraction. Brain. 1983; 106(Pt 1): 197-222.
23. Baron JC, et al. Reversal of focal "misery-perfusion syndrome" by extra-intracranial arterial bypass in hemodynamic cerebral ischemia. A case study with 15O positron emission tomography. Stroke. 1981; 12(4): 454-9.
24. Barber PA, et al. Identification of major ischemic change. Diffusion-weighted imaging versus computed tomography. Stroke. 1999; 30(10): 2059-65.
25. Warach S, et al. Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging. Ann Neurol. 1995; 37(2): 231-41.
26. Kidwell CS, et al. Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging. Ann Neurol. 2000; 47(4): 462-9.
27. Chemmanam T, et al. Ischemic diffusion lesion reversal is uncommon and rarely alters perfusion-diffusion mismatch. Neurology. 2010; 75(12): 1040-7.
28. Campbell BCV, et al. The infarct core is well represented by the acute diffusion lesion: sustained reversal is infrequent. J Cereb Blood Flow Metab. 2012; 32: 50-6.
29. Olivot JM, et al. Optimal Tmax threshold for predicting penumbral tissue in acute stroke. Stroke. 2009; 40(2): 469-75.
30. Christensen S, et al. Optimal perfusion thresholds for prediction of tissue destined for infarction in the combined EPITHET and DEFUSE dataset. Stroke. 2010; 41: e297.
31. Zaro-Weber O, et al. Maps of time to maximum and time to peak for mismatch definition in clinical stroke studies validated with positron emission tomography. Stroke. 2010; 41(12): 2817-21.
32. Davis SM, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008; 7(4): 299-309.
33. Olivot JM, et al. Relationships between infarct growth, clinical outcome, and early recanalization in diffusion and perfusion imaging for understanding stroke evolution (DEFUSE). Stroke. 2008; 39(8): 2257-63.
34. Barber PA, et al. Prediction of stroke outcome with echoplanar perfusion- and diffusion-weighted MRI. Neurology. 1998; 51(2): 418-26.
35. Baird TA, et al. Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. Stroke. 2003; 34(9): 2208-14.
36. Parsons MW, et al. Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. Ann Neurol. 2002; 52(1): 20-8.
37. Allport LE, et al. Elevated hematocrit is associated with reduced reperfusion and tissue survival in acute stroke. Neurology. 2005; 65(9): 1382-7.
38. Singhal AB. Oxygen therapy in stroke: past, present, and future. Int J Stroke. 2006; 1(4): 191-200.
39. Campbell BCV, et al. Assessing response to stroke thrombolysis: validation of 24 hour multimodal MRI. Arch Neurol. 2012; 69: 46-50.
40. Ebinger M, et al. Expediting MRI-based proof-of-concept stroke trials using an earlier imaging end point. Stroke. 2009; 40(4): 1353-8.
41. Campbell BCV, et al. Visual assessment of perfusion-diffusion mismatch is inadequate to select patients for thrombolysis. Cerebrovasc Dis. 2010; 29(6): 592-6.
42. Straka M, Albers GW, Bammer R. Real-time diffusion-perfusion mismatch analysis in acute stroke. J Magn Reson Imaging. 2010; 32(5): 1024-37.
43. Wintermark M, et al. Comparison of admission perfusion computed tomography and qualitative diffusion- and perfusion-weighted magnetic resonance imaging in acute stroke patients. Stroke. 2002; 33(8): 2025-31.
44. Parsons MW, et al. Perfusion computed tomography: prediction of final infarct extent and stroke outcome. Ann Neurol. 2005; 58(5): 672-9.
45. Campbell BCV, et al. Cerebral blood flow is the optimal ct perfusion parameter for assessing infarct core. Stroke. 2011; 42: 3435-40.
46. Bivard A, et al. Defining the extent of irreversible brain ischemia using perfusion computed tomography. Cerebrovasc Dis. 2011; 31(3): 238-45.
47. Albers GW, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol. 2006; 60(5): 508-17.
48. Nagakane Y, et al. EPITHET: Positive result after reanalysis using baseline diffusion-weighted imaging/perfusion-weighted imaging co-registration. Stroke. 2011; 42(1): 59-64.
49. Ma H, et al. A multicentre, randomized, double blinded, placebo controlled phase 3 study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND). Int J Stroke. 2012; 7: 74-80.
50. Parsons MW, et al. Pretreatment diffusion- and perfusion-MR lesion volumes have a crucial influence on clinical response to stroke thrombolysis. J Cereb Blood Flow Metab. 2010; 30(6): 1214-25.
51. Campbell BCV, et al. Regional very low cerebral blood volume predicts hemorrhagic transformation better than diffusion-weighted imaging volume and thresholded apparent diffusion coefficient in acute ischemic stroke. Stroke. 2010; 41(1): 82-8.
52. Lansberg MG, et al. RAPID automated patient selection for reperfusion therapy: a pooled analysis of the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) and the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) study. Stroke. 2011; 42(6): 1608-14.
53. De Silva DA, et al. The benefits of intravenous thrombolysis relate to the site of baseline arterial occlusion in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET). Stroke. 2010; 41(2): 295-9.
54. Albers G, et al. Results of DEFUSE 2: imaging endpoints. Stroke. 2012; 43: A52.
55. Mishra NK, et al. Mismatch-based delayed thrombolysis: a meta-analysis. Stroke. 2010; 41(1): e25-33.